- Home
- GOSS vs RENE Comparison
GOSS vs RENE Comparison
Compare GOSS & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- RENE
- Stock Information
- Founded
- GOSS 2015
- RENE 2021
- Country
- GOSS United States
- RENE United States
- Employees
- GOSS N/A
- RENE N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- RENE Blank Checks
- Sector
- GOSS Health Care
- RENE Finance
- Exchange
- GOSS Nasdaq
- RENE Nasdaq
- Market Cap
- GOSS 212.8M
- RENE 151.4M
- IPO Year
- GOSS 2019
- RENE 2022
- Fundamental
- Price
- GOSS $1.34
- RENE $11.81
- Analyst Decision
- GOSS Strong Buy
- RENE
- Analyst Count
- GOSS 5
- RENE 0
- Target Price
- GOSS $9.20
- RENE N/A
- AVG Volume (30 Days)
- GOSS 1.8M
- RENE 5.5K
- Earning Date
- GOSS 05-06-2025
- RENE 01-01-0001
- Dividend Yield
- GOSS N/A
- RENE N/A
- EPS Growth
- GOSS N/A
- RENE 42.92
- EPS
- GOSS N/A
- RENE 0.43
- Revenue
- GOSS $105,322,000.00
- RENE N/A
- Revenue This Year
- GOSS N/A
- RENE N/A
- Revenue Next Year
- GOSS N/A
- RENE N/A
- P/E Ratio
- GOSS N/A
- RENE $27.20
- Revenue Growth
- GOSS N/A
- RENE N/A
- 52 Week Low
- GOSS $0.50
- RENE $11.09
- 52 Week High
- GOSS $1.56
- RENE $11.81
- Technical
- Relative Strength Index (RSI)
- GOSS 59.37
- RENE 66.68
- Support Level
- GOSS $1.10
- RENE $11.77
- Resistance Level
- GOSS $1.29
- RENE $11.78
- Average True Range (ATR)
- GOSS 0.13
- RENE 0.01
- MACD
- GOSS -0.01
- RENE 0.00
- Stochastic Oscillator
- GOSS 55.06
- RENE 100.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About RENE Cartesian Growth Corporation II
Cartesian Growth Corp II is a blank check company.